CG Oncology, Inc.
CGONNext catalyst
Cretostimogene Grenadenorepvec
High-Risk Non-Muscle-Invasive Bladder Cancer
Get an email about CGON's next catalysts
Track CG Oncology (CGON) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 0 past
CGON Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.86 | FQ end Sep/2026 | Call: tbd
Cretostimogene Grenadenorepvec Phase 3 Est. Readout
Estimated primary completion for Cretostimogene Grenadenorepvec trial (NCT06111235) in Non Muscle Invasive Bladder Cancer. Topline data typically follows completion by weeks to months.
SourceCretostimogene Grenadenorepvec Phase 2 Est. Readout
Primary completion for Cretostimogene Grenadenorepvec trial (NCT06567743) in High-Risk Non-Muscle-Invasive Bladder Cancer
SourceMarket Overview
Stock performance and key metrics
Cretostimogene Grenadenorepvec
High-Risk Non-Muscle-Invasive Bladder Cancer
CG0070
Non Muscle Invasive Bladder Cancer
Ivaltinostat
Metastatic Pancreatic Adenocarcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cretostimogene Grenadenorepvec | Phase 3 | High-Risk Non-Muscle-Invasive Bladder Cancer | - | - |
CG0070 | Phase 2 | Non Muscle Invasive Bladder Cancer | - | - |
Ivaltinostat | Phase 2 | Metastatic Pancreatic Adenocarcinoma | - | - |
Frequently asked questions
What is in CG Oncology, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in CG Oncology, Inc.'s (CGON) pipeline across Phase 3, Phase 2. Its lead program is Cretostimogene Grenadenorepvec (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CG Oncology, Inc.'s next FDA catalyst?→
CG Oncology, Inc.'s (CGON) next tracked catalyst is a Phase 3 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CGON biotech catalysts?→
Add CGON to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CG Oncology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.